Top Markets
#1 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +17.95%
#2 clBTC clBTC +12.15%
#3 OpenEden OpenEden +11.48%
#4 BasedHype BasedHype +11.14%
#5 Wrapped Ether (Mantle Bridge) Wrapped Ether (Mantle Bridge) +8.73%
#6 Not in Employment, Education, or Training Not in Employment, Education, or Training +8.41%
#7 Mantle Staked Ether Mantle Staked Ether +8.34%
#8 Mantle Restaked ETH Mantle Restaked ETH +8.01%
#9 MarsCoin MarsCoin +6.65%
#10 EfficientFrontier EfficientFrontier +4.93%
Coin of the day
FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock)
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
ObsEva S.A. ObsEva S.A.

ObsEva S.A.

OBSN
Classifica tra le azioni #40302
ObsEva S.A. is a biopharmaceutical company focused on developing and... ObsEva S.A. is a biopharmaceutical company focused on developing and commercializing groundbreaking therapies for women facing challenges in reproductive health and pregnancy. Its product pipeline includes Linzagolix, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist currently in Phase III clinical trials. Linzagolix is being evaluated for its efficacy in treating pain associated with endometriosis and heavy menstrual bleeding linked to uterine fibroids in pre-menopausal women. The firm is also progressing with Ebopiprant, an oral and selective prostaglandin F2a (PGF2a) receptor antagonist, which is in Phase II clinical trials as a once-daily treatment for preterm labor occurring between 24 and 34 weeks of gestational age. Additionally, ObsEva is developing Nolasiban, an oral oxytocin receptor antagonist in Phase I clinical trials, aimed at enhancing clinical pregnancy and live birth rates for women undergoing in vitro fertilization. ObsEva S.A. was founded in 2012 and maintains its headquarters in Geneva, Switzerland.
Prezzo delle azioni
$0.00156067
Ultima sincronizzazione: 2024-05-03
Capitalizzazione di mercato
$182.87K
Variazione (1 giorno)
-72.69%
Variazione (1 anno)
0.00%
Paese
CH
Scambia ObsEva S.A. (OBSN)

Categoria

Healthcare
Ricavi di ObsEva S.A. (OBSN)
Ricavi nel Aug 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di ObsEva S.A., i ricavi attuali dell'azienda (TTM) sono pari a 0. Nel 2026, l'azienda ha registrato ricavi di 0 uguale a i ricavi dell'anno 2026, che erano pari a 0. I ricavi rappresentano l'importo totale generato dalla vendita di beni o servizi. A differenza degli utili, le spese non vengono detratte.
Storico dei ricavi per ObsEva S.A. da 2026 a 2026
Ricavi alla fine di ogni anno
Anno Ricavi Cambia
Non abbastanza dati per le date fornite.
Ricavi di aziende simili o concorrenti
Azienda Ricavi Differenza nei ricavi Il paese
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B -
BE